ArticleMolecular and cellular biology2004
Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent acetylation of p53.
Article in Molecular and cellular biology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 78 citations in OpenAlex.
- Regulatory role of IRF2 in proliferation and invasion of nasopharyngeal carcinoma and its underlying mechanism.iScience · 2026Article
- IRF1 mediates airway epithelial innate memory through priming BRD4- EP300 activity.Frontiers in immunology · 2026Article
- Metabolic reprogramming tips vaccinia virus infection outcomes by stabilizing interferon-γ induced IRF1.PLoS pathogens · 2024Article
- Exploring the role of CITED transcriptional regulators in the control of macrophage polarization.Frontiers in immunology · 2024Review
- IRF1 regulates self-renewal and stress responsiveness to support hematopoietic stem cell maintenance.Science advances · 2023Article
- Genetic Variants Associated with Longitudinal Cognitive Performance in Older Breast Cancer Patients and Controls.Cancers · 2023Article
- Insights into Regulators of p53 Acetylation.Cells · 2022Review
- Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer.Clinical epigenetics · 2022Article
- Purine-Induced IFN-γ Promotes Uric Acid Production by Upregulating Xanthine Oxidoreductase Expression.Frontiers in immunology · 2022Article
- Article
- Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Joint Transcriptomic Analysis of Lung Cancer and Other Lung Diseases.Frontiers in genetics · 2019Article
- RNase H2, mutated in Aicardi-Goutières syndrome, promotes LINE-1 retrotransposition.The EMBO journal · 2018Article
- Discovery and validation of information theory-based transcription factor and cofactor binding site motifs.Nucleic acids research · 2017Article
- HIV-1 Tat Recruits HDM2 E3 Ligase To Target IRF-1 for Ubiquitination and Proteasomal Degradation.mBio · 2016Article
- Identifying novel genes and chemicals related to nasopharyngeal cancer in a heterogeneous network.Scientific reports · 2016Article
- MicroRNA-23b Promotes Avian Leukosis Virus Subgroup J (ALV-J) Replication by Targeting IRF1.Scientific reports · 2015Article
- Interferon regulatory factor 1 marks activated genes and can induce target gene expression in systemic lupus erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2015Article
- p53 Acetylation: Regulation and Consequences.Cancers · 2014Review
- In silico analysis of autoimmune diseases and genetic relationships to vaccination against infectious diseases.BMC immunology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferon regulatory factor 1 (IRF-1) and p53 control distinct sets of downstream genes; however, these two antioncogenic transcription factors converge to regulate p21 gene expression and to inhibit tumor formation. Here we investigate the mechanism by which IRF-1 and p53 synergize at the p21 promoter and show that stimulation of p21 transcription by IRF-1 does not require its DNA-binding activity but relies on the ability of IRF-1 to bind the coactivator p300 and to stimulate p53-dependent transcription by an allosteric mechanism. Deletion of the p300-binding sites in IRF-1 eliminates the ability of IRF-1 to stimulate p53 acetylation and associated p53 activity. Complementing this, small peptides derived from the IRF-1-p300 interface can bind to p300, stabilize the binding of p300 to DNA-bound p53, stimulate p53 acetylation in trans, and up-regulate p53-dependent activity from the p21 promoter. The nonacetylatable p53 mutant (p53-6KR) cannot be stimulated by IRF-1, further suggesting that p53 acetylation is the mechanism whereby IRF-1 modifies p53 activity. These data expand the core p300-p53 protein LXXLL and PXXP interface by including an IRF-1-p300 interface as an allosteric modifier of DNA-dependent acetylation of p53 at the p21 promoter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.